To Compare the Efficacy, Pharmacokinetics and Safety Between CT-P13 and China Approved Remicade When Co-administered With Methotrexate in Patients With Active Rheumatoid Arthritis

A Randomized, Controlled, Double-Blind, Phase 3 Study to Compare the Efficacy, Pharmacokinetics and Safety Between CT-P13 and China Approved Remicade When Co-administered With Methotrexate in Patients With Active Rheumatoid Arthritis

To demonstrate that CT-P13 is equivalent to China-approved Remicade at Week 14, in terms of efficacy as determined by clinical response according to the change from baseline in disease activity.

Inclusion Criteria:

• Has a diagnosis of rheumatoid arthritis
• Has active disease as defined in DAS28 Criteria

Exclusion Criteria:

• Has a history of tuberculosis (TB) or a current diagnosis of TB
• Has previously received a biological agent
• Has previously received a tumor necrosis factor alpha (TNF α) inhibitor
• Allergies to any of the excipients of infliximab or hypersensitivity to murine and/or human proteins or immunoglobulin products
• Pregnant or lactating